Trial Profile
A phase I study of irinotecan, bevacizumab and biweekly TAS-102 in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplatin
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 20 Aug 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Irinotecan (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions
- Acronyms MODURATE
- 02 Jul 2022 Results presented at the 24th World Congress on Gastrointestinal Cancer
- 31 May 2021 Status changed from recruiting to active, no longer recruiting.
- 04 Jul 2020 Results (n=15) of preliminary report presented at the 22nd World Congress on Gastrointestinal Cancer